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Abstract
Objective:  Literature  review  of  new  genes  related  to  osteogenesis  imperfecta  (OI)  and  update
of its  classiﬁcation.
Sources:  Literature  review  in  the  PubMed  and  OMIM  databases,  followed  by  selection  of  relevant
references.
Summary  of  the  ﬁndings: In  1979,  Sillence  et  al.  developed  a  classiﬁcation  of  OI  subtypes  based
on clinical  features  and  disease  severity:  OI  type  I,  mild,  common,  with  blue  sclera;  OI  type
II,  perinatal  lethal  form;  OI  type  III,  severe  and  progressively  deforming,  with  normal  sclera;
and  OI  type  IV,  moderate  severity  with  normal  sclera.  Approximately  90%  of  individuals  with
OI  are  heterozygous  for  mutations  in  the  COL1A1  and  COL1A2  genes,  with  dominant  pattern  of
inheritance  or  sporadic  mutations.  After  2006,  mutations  were  identiﬁed  in  the  CRTAP,  FKBP10,
LEPRE1,  PLOD2,  PPIB,  SERPINF1,  SERPINH1,  SP7,  WNT1,  BMP1,  and  TMEM38B  genes,  associated
with  recessive  OI  and  mutation  in  the  IFITM5  gene  associated  with  dominant  OI.  Mutations  in  PLS3
were  recently  identiﬁed  in  families  with  osteoporosis  and  fractures,  with  X-linked  inheritance
pattern.  In  addition  to  the  genetic  complexity  of  the  molecular  basis  of  OI,  extensive  phenotypic
variability  resulting  from  individual  loci  has  also  been  documented.
Conclusions:  Considering  the  discovery  of  new  genes  and  limited  genotype-phenotype  corre-
lation, the  use  of  next-generation  sequencing  tools  has  become  useful  in  molecular  studies  of
OI  cases.  The  recommendation  of  the  Nosology  Group  of  the  International  Society  of  Skele-
tal  Dysplasias  is  to  maintain  the  classiﬁcation  of  Sillence  as  the  prototypical  form,  universally
accepted  to  classify  the  degree  of  severity  in  OI,  while  maintaining  it  free  from  direct  molecular
reference.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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PALAVRAS-CHAVE
Osteogênese
imperfeita;
Osteocondrodisplasias;
Colágeno  tipo  1
O  que  há  de  novo  em  genética  e  classiﬁcac¸ão  de  osteogênese  imperfeita?
Resumo
Objetivo:  Revisão  da  literatura  sobre  novos  genes  relacionados  à  osteogênese  imperfeita  (OI)
e  atualizac¸ão  da  sua  classiﬁcac¸ão.
Fonte dos  dados:  Revisão  nas  bases  de  dados  do  PUBMED  e  OMIM  com  selec¸ão  de  referências
relevantes.
Síntese dos  dados: Sillence  et  al.,  em  1979,  desenvolveram  uma  classiﬁcac¸ão  dos  subtipos  de
OI baseada  em  características  clínicas  e  gravidade  da  doenc¸a:  OI  tipo  I,  forma  leve,  comum,  com
escleras  azuladas;  OI  tipo  II,  forma  perinatal  letal;  OI  tipo  III,  forma  grave  e  progressivamente
deformante com  esclera  normal;  e  OI  tipo  IV,  forma  de  gravidade  moderada  com  esclera  normal.
Cerca  de  90%  dos  indivíduos  com  OI  são  heterozigotos  para  mutac¸ões  em  COL1A1  e  COL1A2,  com
padrão  de  heranc¸a dominante  ou  esporádico.  A  partir  de  2006  foram  identiﬁcadas  mutac¸ões  nos
genes  CRTAP,  FKBP10,  LEPRE1,  PLOD2,  PPIB,  SERPINF1,  SERPINH1,  SP7,  WNT1,  BMP1  e  TMEM38B
associadas  à  OI  recessiva  e  mutac¸ão  em  IFITM5  associada  à  OI  dominante.  Mutac¸ões  em  PLS3
foram  identiﬁcadas  recentemente  em  famílias  com  osteoporose  e  fraturas,  com  padrão  de
heranc¸a ligado  ao  X.  Além  da  complexidade  genética  das  bases  moleculares  das  OI,  extensa
variabilidade  fenotípica  resultante  de  loci  individuais  também  tem  sido  documentada.
Conclusões: Face  à  descoberta  de  novos  genes  e  à  correlac¸ão  genótipo-fenótipo  limitada,  o
uso de  ferramentas  de  sequenciamento  de  nova  gerac¸ão  torna-se  útil  no  estudo  molecular  de
casos  de  OI.  A  recomendac¸ão  do  Grupo  de  Nosologia  da  Sociedade  Internacional  de  Displasias
Esqueléticas é  manter  a  classiﬁcac¸ão  de  Sillence  como  a  forma  prototípica  e  universalmente
aceita para  classiﬁcar  o  grau  de  gravidade  na  OI,  e  libertá-la  de  referência  molecular  direta.
© 2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Osteogenesis  imperfecta  (OI)  is  a  group  of  clinically  and
genetically heterogeneous  diseases  characterized  by  sus-
ceptibility  to  bone  fractures,  with  variable  degree  of
severity and  presumed  or  proven  defects  in  collagen  type
I biosynthesis.  Other  manifestations  include  dentinogene-
sis imperfecta,  blue  sclerae,  and  short  stature,  as  well
as hearing  loss  in  adulthood.  Clinical  manifestations  range
from severe  cases  with  perinatal  lethality  to  asymptomatic
individuals with  mild  predisposition  to  fractures,  normal
stature, and  normal  life.1
Overall,  the  incidence  of  the  different  types  of  OI  is
approximately 1  in  15,000-20,000  births  and  most  cases  are
due to  autosomal  dominant  inheritance  with  mutations  in
COL1A1 or  COL1A2  genes,  which  encode  the  1  (I)  and  2
(I) chains  of  type  I  collagen.1
Type  I  collagen,  the  main  structural  protein  of  the  extra-
cellular matrix  of  bone,  skin,  and  tendons,  consists  of  two
pro--1 chains  and  one  pro--2  chain  that  interweave,  form-
ing a  rigid  triple  helix.  Each    chain  contains  N-(amino)  and
C-(carboxy) terminal  propeptides  and  a  central  domain  con-
sisting of  338  repeats  of  Gly-XY,  where  X  and  Y  exclude
cysteine and  tryptophan,  and  which  often  are,  respectively,
proline and  hydroxyproline.  Glycine,  as  the  smallest  amino
acid, is  the  only  residue  that  can  occupy  the  axial  position
of the  triple  helix,  so  that  any  change  in  a  glycine  residue
will result  in  the  disruption  of  the  helical  structure.2,3Mutations  in  COL1A1  and  COL1A2  genes  alter  the  struc-
ture or  the  amount  of  type  I  collagen,  resulting  in  a  skeletal
phenotype that  ranges  from  subclinical  to  lethal.1
D
d
fThese  patients  exhibit  qualitative  and  quantitative
bnormalities  in  type  I  collagen  due  to  the  dominant  neg-
tive effect  of  the  mutation,  as  the  mutant  pro-  chains
re incorporated  into  the  type  I  procollagen  molecules  that
lso contain  normal  pro-  chains.  As  a  rule,  when  there
s substitution  of  glycine  in  the  1 chain,  the  phenotype
ill depend  on  the  position  of  the  substitution:  C-terminal
ubstitutions result  in  severe  disease  phenotype,  and  N-
erminal substitutions  yield  milder  phenotypes.4,5 Residues
ith large  lateral  chains  or  charged  residues  are  highly  dis-
uptive of  the  triple  structure,  regardless  of  where  they
re located.  Different  phenotypes  have  been  found  with  the
ame mutation.6
In  a  consortium  created  in  2007  to  study  OI-causing  muta-
ions in  type  I  collagen  genes,  1,832  independent  mutations
ere identiﬁed;  682  resulted  in  the  substitution  of  glycine
esidues in  the  triple  helix  domain  of  the  encoded  protein,
nd 150  in  splice  sites.6
Based  on  clinical,  radiographic,  and  skeletal  ﬁndings,
ode of  inheritance,  and  molecular  genetic  analyses,  new
I types  have  been  identiﬁed  since  2006  through  exome
equencing. The  present  study  aimed  to  review  the  classiﬁ-
ation of  OI  and  to  update  new  related  genes.  The  PubMed
nd Online  Mendelian  Inheritance  in  Man  (OMIM)  databases
ere used.7
illence  Classiﬁcationue  to  considerable  phenotypic  variability,  Sillence  et  al.8,9
eveloped  a  classiﬁcation  of  OI  subtypes  based  on  clinical
eatures and  disease  severity  (Table  1):  OI  type  I,  mild,
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Table  1  Classiﬁcation  of  OI.a
Type  General  manifestations  Speciﬁc  manifestations
I-  Autosomal  dominant  inheritance
with blue  sclera.
Variable bone  fragility,  blue  sclera,
early deafness,  mild  stunting.
I-A:  normal  teeth.
I-B and  I-C:  dentinogenesis  imperfecta.
II- Perinatal  lethal  form,
radiographically characterized  by
crumpled  femora  and  beaded  ribs.
Extreme  bone  fragility,  perinatal
death.
II-A: short  and  widened  long  bones  with
fractures,  wide  ribs  with  fractures.
II-B: short  and  widened  long  bones  with
fractures,  ribs  with  sparse  fractures.
II-C:  thin  long  bones  with  fractures,  thin
ribs.
III-  Progressively  deforming,  with
normal sclera.
Moderate  to  severe  bone  fragility,
blue  sclera  in  infancy.
Early-onset kyphoscoliosis.
Dentinogenesis  imperfecta  may  be  present.
IV- Autosomal  dominant  inheritance
with normal  sclera.
Bone fragility,  moderate  to  severe
deformity  of  the  long  bones  and
spinal  column,  white  sclera,
moderate to  severe  stunting.
IV-A: normal  teeth.
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ga Modiﬁed from Sillence et al.8
ommon, with  blue  sclera;  OI  type  II,  perinatal  lethal  form;
I type  III,  severe  and  progressively  deforming,  with  normal
clera; and  OI  type  IV,  moderate  severity  with  normal  sclera.
he classiﬁcation  of  Sillence  has  been  repeatedly  revised
hen new  causative  genes  for  OI  are  identiﬁed.
xpanded  Classiﬁcation
he  molecular  genetic  classiﬁcation  of  OI  has  shown  to  be
ery heterogeneous,  with  different  patterns  of  inheritance
nd wide  variability  of  clinical  severity.10
Glorieux  et  al.11 described  an  autosomal  dominant  form
f OI,  similar  to  OI  Sillence  type  IV,  but  with  distinct  clinical,
istological, and  molecular  characteristics.  No  mutations
ere found  in  COL1A1  and  COL1A2  and,  therefore,  it  was
alled OI  type  V  (OMIM  #610967)  by  the  authors.  Approx-
mately 65%  of  affected  individuals  develop  hyperplastic
allus after  fractures  or  surgical  interventions,  considered
 pathognomonic  characteristic.12 Only  in  2012  were  IFITM5
utations identiﬁed  in  patients  with  type  V  OI,  the  gene
ncoding interferon-induced  transmembrane  protein  5,  by
equencing of  the  entire  exome.12--14 The  encoded  protein
as a  role  in  early  mineralization,  but  its  mechanism  remains
nknown.10
In  2006,  a  CRTAP  gene  mutation  was  identiﬁed  as  the
rst genetic  cause  of  lethal  recessive  OI.15 Since  then,  new
utations in  genes  that  cause  recessive  OI  have  been  identi-
ed by  exome  sequencing,  such  as  FKBP10,  LEPRE1,  PLOD2,
PIB, SERPINF1,  SERPINH1,  SP,  BMP1,  and  TMEM38B.  Each
f these  genes  received  an  OI  type  number  in  the  OMIM
atabase, following  the  sequence  numbers  of  the  Sillence
lassiﬁcation.
OI type  VI  (OMIM  #613982)  is  an  autosomal  recessive  form
f the  disease  that  can  be  caused  by  a  homozygous  muta-
ion in  the  gene  SERPINF1  in  chromosome  17p13.3,  causing
 mineralization  defect.14 According  to  the  classiﬁcation  of
illence et  al.,  the  phenotype  is  compatible  with  type  IV  or
ype III.16,17
b
i
o
sIV-B: dentinogenesis  imperfecta.
OI  type  VII  (MIM  #610682)  is  a  lethal  autosomal  recessive
orm of  OI,  caused  by  a  mutation  in  CRTAP  gene  in  homozy-
osity or  compound  heterozygosity  in  chromosome  3p22.  It
ccounts for  2%  to  3%  of  cases  of  lethal  OI.15
Cabral  et  al.18 described  a  form  of  autosomal  recessive
I, called  OI  type  VIII  (OMIM  #610915),  which  is  charac-
erized by  white  sclera,  severe  growth  impairment,  very
oor skeletal  mineralization,  and  bulbous  metaphyses.  This
orm is  caused  by  mutations  in  the  gene  encoding  leprecan
LEPRE1) in  chromosome  1p34.2,  associated  with  severe  or
ethal OI.
OI type  IX  (OMIM  #259440)  is  an  autosomal  recessive  form
f OI  corresponding  to  clinically  severe  types  II/III  of  the  Sil-
ence classiﬁcation.19 There  are  no  reports  of  dentinogenesis
mperfecta. It  can  be  caused  by  a  homozygous  mutation  in
he PPIB  gene  in  chromosome  15q22.31.
OI  type  X  (OMIM  #613848)  is  an  autosomal  recessive
orm of  the  disease  that  can  be  caused  by  a homozygous
utation in  the  gene  SERPINH1  in  chromosome  11q13.5.
t is  characterized  by  bone  deformities  and  multiple  frac-
ures, generalized  osteopenia,  dentinogenesis  imperfecta,
nd blue  sclera.  SERPINH1  encodes  a  collagen-binding  pro-
ein that  acts  as  a  chaperone  in  the  endoplasmic  reticulum
nd thus,  individuals  with  mutations  in  this  gene  have  cells
hat do  not  produce  overmodiﬁed  type  I  collagen.20
OI  type  XI  (OMIM  #610968)  is  an  autosomal  recessive  form
f the  disease  caused  by  a  homozygous  mutation  in  the
KBP10 gene  in  chromosome  17q21,  also  related  to  a  chap-
rone defect.1 Patients  with  type  OI  type  XI  have  severe
rogressive deformation  and  may  have  joint  contractures.
atients do  not  have  dentinogenesis  imperfecta.21--23
OI  type  XII  (OMIM  #613849)  is  an  autosomal  reces-
ive form,  which  can  be  caused  by  mutation  in  the  SP7
ene in  chromosome  12q13.13.  It  is  clinically  characterized
y recurrent  fractures,  mild  bone  deformities,  general-
zed osteoporosis,  delayed  eruption  of  teeth,  absence
f dentinogenesis  imperfecta,  normal  hearing,  and  white
clera.24
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Table  2  Expanded  classiﬁcation  of  OI.a
Type  of  OI  Inheritance  Phenotype  Genetic  defect
Classical  Sillence  Types
I AD  Mild  COL1A1
X-linked  Mild  PLS3
II  AD  Letal  COL1A1  or  COL1A2
III  AD  Progressive  deformity  COL1A1  or  COL1A2
IV  AD  Moderate  COL1A1  or  COL1A2
V  AD  Moderate,  hypertrophic  callus  and
ossiﬁcation  of  the  interosseous  membrane
IFITM5
VI  AR  Moderate  to  severe SERPINF1
VII  AR  Severe  to  letal CRTAP
VIII  AR  Severe  to  letal  LEPRE1
IX  AR  Severe  to  letal  PPIB
X  AR  Severe  SERPINH1
XI  AR  Progressive  deformity,  contractures  FKBP10
XII  AR  Moderate  SP7
XIII  AR  Severe  BMP1
XIV  AR  Variable  severity  TMEM38B
XV  AR
AD
Variable  severity
Early-onset  osteoporosis
WNT1
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as shown  in  Table  3,  OI  was  grouped  into  ﬁve  clinical  cate-AD, autosomal dominant; AR, autosomal recessive.
a Adapted from Forlino et al.1
OI  type  XIII  (OMIM  #614856)  was  described  as  caused  by
a homozygous  mutation  in  the  gene  BMP1  in  chromosome
8p21.25,26
Shaheen  et  al.27 described  OI  type  XIV  (OMIM  #  615066),
an autosomal  recessive  form  characterized  by  varying
degrees of  severity  with  multiple  fractures  and  osteopenia,
with normal  dentition,  sclera,  and  hearing.  Fractures  occur
prenatally or  at  approximately  6  years  of  age.  It  is  caused  by
a homozygous  mutation  in  the  gene  TMEM38B  in  chromosome
9q31.
OI type  XV  (OMIM  #615220)  has  been  designated  based
on the  identiﬁcation  of  mutations  in  WNT1.28--30 Keupp
et al.30 reported  that  WNT1  hypofunctional  alleles  result
in phenotypes  with  low  bone  mass  in  humans.  They  veri-
ﬁed that  mutations  in  the  recessive  inherited  gene  lead  to
phenotypes of  varying  severity,  ranging  from  mild  to  progres-
sively deforming,  which  can  occasionally  lead  to  early  infant
death. They  also  detected  families  that  had  early  osteoporo-
sis with  the  autosomal  dominant  pattern  of  inheritance,  with
a heterozygous  mutation  in  WNT1.
The  recessive  forms  of  OI  with  moderate  to  lethal  phen-
otypes are  caused  by  defects  in  genes  whose  products
interact with  collagen  type  I.  Most  recessive  cases  have  null
mutations in  genes  encoding  proteins  involved  in  prolyl  3-
hydroxylation of  collagen  (CRTAP,  LEPRE1,  and  PPIB),  or  in
those responsible  for  the  correct  helical  folding  (FKBP10
and SERPINH1).  Types  VII,  VIII,  and  IX  are  caused  by  defects
in 3-hydroxylation.1 The  genotype-phenotype  correlation  in
recessive forms  has  been  suggested.31
In  2013,  PLS3  mutations  were  identiﬁed  in  families  with
osteoporosis and  fractures  manifesting  in  childhood,  with  an
X-linked pattern  of  inheritance.32
g
s
B
tTable  2  summarizes  the  classiﬁcation  based  on  the
nvolved genes.
In  2010,  van  Dijk  et  al.33 proposed  a  revised  classiﬁcation
f OI,  mentioning  the  causative  gene  and  the  correspond-
ng clinical  picture  only  for  types  I  to  VI.  Types  VII  and  VIII
ere excluded,  as  those  types  were  added  by  genetic  crite-
ia, although  their  clinical  and  radiological  ﬁndings  were
ndistinguishable from  those  in  types  II  to  IV.  The  proposed
lassiﬁcation leaves  room  for  new  genes  discovered  as  the
ause of  OI  until  the  full  extent  of  heterogeneity  is  known.34
I  Classiﬁcation  by  the  International  Society  of
keletal Dysplasias
ue  to  the  high  genetic  complexity  of  the  molecular  basis
f OI  and  the  extensive  phenotypic  variability  resulting  from
ndividual loci  described  in  recent  years,  it  seemed  impos-
ible to  maintain  correlations  between  Sillence  types  and
heir molecular  basis.  But  the  proliferation  of  OI  types
o reﬂect  each  gene  separately,  supported  by  some,  has
ecome more  confusing  than  useful  in  clinical  practice.  For
hese reasons,  in  2009  the  Nosology  Group  of  the  Interna-
ional Society  of  Skeletal  Dysplasias  recommended  main-
aining the  classiﬁcation  of  Sillence  as  the  prototypical  and
niversally accepted  form  to  classify  the  degree  of  OI  sever-
ty, and  freeing  it  from  direct  molecular  reference.35 Thus,ories, and  the  several  genes  that  can  cause  OI  were  listed
eparately. In  the  present  study,  the  genes  IFITM5,  SERPINF1,
MP1, WNT1,  TMEM38B,  and  PLS3  were  added  to  the  original
able, as  they  were  discovered  after  its  publication.
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Table  3  OI  classiﬁcation  according  to  the  International  Society  of  Skeletal  Dysplasiasa with  addition  of  newly  discovered  genes.
Osteogenesis  Imperfecta  Inheritance  Genes
Nondeforming  osteogenesis  imperfecta  (type  I)  AD
X-linked
COL1A1,  COL1A2
PLS3
Perinatal  lethal  (type  II)  AD,  AR  COL1A1,  COL1A2,  CRTAP,  LEPRE1,  PPIB,  BMP1
Progressively  deforming  (type  III)  AD,  AR  COL1A1,  COL1A2,  CRTAP,  LEPRE1,  PPIB,
FKBP10,  SERPINH1,  SERPINF1,  WNT1
Moderate (type  IV) AD,  AR COL1A1,  COL1A2,  CRTAP,  FKBP10,  SP7,
SERPINF1,  WNT1,  TMEM38B
With calciﬁcation  of  the  interosseous  membrane
and/or  hypertrophic  callus  (type  V)
AD  IFITM5
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1AD, autosomal dominant; AR, autosomal recessive.
a Warman et al.35
onclusion
n  practice,  in  spite  of  the  complex  genotypic  variability
f OI  demonstrated  in  recent  years,  its  phenotypes  are
till classiﬁed  according  to  Sillence.  Genotypic  investiga-
ion should  be  indicated,  especially  in  cases  suggesting
utosomal recessive  inheritance,  aimed  at  genetic  counsel-
ng. The  molecular  study  should  be  performed  using  Sanger
equencing of  the  several  new  genes,  or  by  next-generation
equencing. Exome  sequencing  is  useful  when  there  is  no
anel of  available  genes,  or  when  the  involved  genes  are
ot known.
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